Drug intelligence / Profile preview

MEDI7352

Development stage: Phase 2
Lead developer: AstraZeneca
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

MEDI7352 is a bispecific monoclonal antibody designed to simultaneously inhibit nerve growth factor (NGF) and tumor necrosis factor alpha (TNF-α). By targeting both NGF and TNF-α pathways, it aims to modulate pain signaling and inflammation. The drug was developed for the treatment of chronic pain conditions such as painful osteoarthritis of the knee and painful diabetic neuropathy. It was initially developed by MedImmune (a subsidiary of AstraZeneca) and later advanced by AstraZeneca. Clinical trials have evaluated its safety, tolerability, pharmacokinetics, and efficacy in these indications[1][2][3][4][5].

Targets

NGF (Nerve growth factor)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on MEDI7352.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDI7352.

Explore the full profile